Additional file 1: of DNA methylation patterns associated with oxidative stress in an ageing population

Supplementary Data. Figure S1. Plot showing the first two PC components of the PIVUS genotype data with the 1000G multi population reference panel. Figure S3. Comparison of regression coefficients from the primary and secondary models (additionally adjusted for BMI) for oxidative marker BCD-LDL. Table S9. Enrichment in JASPAR transcription factor binding site motifs in genes annotated to oxidative stress associated CpGs (Bonferroni-adjusted p-value < 0.05). Table S10. Enriched biological process among genes annotated to oxidative marker associated CpGs (adjusted p-value < 0.05). Table S11. Enriched annotation clusters among genes annotated to oxidative marker CpGs (enrichment score > 1). Table S12. Significant lead cis-meQTL SNPs of oxidative marker CpGs (FDR <0.05). Table S13. Overlap across genotype-CpG (FDR <0.05), genotype-phenotype (p-value <0.001), and CpG-phenotype (FDR <0.05) results. (DOCX 135 kb

Additional file 3: of DNA methylation patterns associated with oxidative stress in an ageing population

Supplemental Tables. Table S1. Methylation sites associated with TGSH (FDR <0.05). Table S2. Methylation sites associated with GSH (FDR <0.05. Table S3. Methylation sites associated with GSSG (FDR <0.05). Table S4. Methylation sites associated with ratio of GSSG-to-GSH (FDR <0.05). Table S5. Methylation sites associated with levels of HCY (FDR <0.05). Table S6. Methylation sites associated with levels of oxLDL (FDR <0.05). Table S7. Methylation sites associated with levels of CD (FDR <0.05). Table S8: Methylation sites associated with BCD-LDL (FDR <0.05). (XLS 185 kb

Change in STOPP and START from admission to discharge for <5- and ≥5-drugs subgroups.

<p>SD, Standard deviation.</p>a<p>Change from admission calculated as STOPP/START Score at discharge – STOPP/START Score on admission.</p>b<p>p-values from rank analysis of covariance for the effect of group (Intervention or Control) on change from admission, adjusted for the score on admission.</p><p>Change in STOPP and START from admission to discharge for <5- and ≥5-drugs subgroups.</p

Baseline characteristics for the patients in the <5 drugs and ≥5 drugs subgroups.

<p>Baseline characteristics for the patients in the <5 drugs and ≥5 drugs subgroups.</p

Subgroup analyses for the number of ED-visits.

a<p>Rate ratios, 95% confidence intervals and p-values from poisson regression models with group, subgroup factor and their interaction as independent variables.</p><p>Subgroup analyses for the number of ED-visits.</p

Overview of the metabolites being associated with at least one of the five MetS criteria.

The criteria are given together with sum of criteria. The table was sorted on sum of criteria. (DOCX)</p

Basic characteristics of the samples.

Means and (SD) are given, or proportions in %.</p

Relationships between the 15 validated metabolites being related to all five components in the metabolic syndrome (MetS) and prevalent MetS in a meta-analysis of the PIVUS and POEM samples.

The results are sorted on p-value. A star following the p-value denotes that the metabolite shows a false discovery rate (FDR)<0.05.</p

Relationships between the 15 validated metabolites being related to all five components in the metabolic syndrome (MetS) and incident atherosclerotic cardiovascular disease in the EpiHealth cohort.

Relationships between the 15 validated metabolites being related to all five components in the metabolic syndrome (MetS) and incident atherosclerotic cardiovascular disease in the EpiHealth cohort.</p

Relationships between the 15 validated metabolites being related to all five components in the metabolic syndrome (MetS) and fasting glucose (GLU), HDL-cholesterol, systolic blood pressure (SBP), triglycerides (TG) and waist circumference (WC).

The estimates are from the validation step in the SCAPIS-Malmö cohort. No relationship for the metabolite glucose vs the GLU criteria is shown. (DOCX)</p